Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE	
STATEMENT BY APPLICANT	
( Not for submission under 37 CFR 1.99)	

Application Number		10507417			
Filing Date		2005-02-03			
First Named Inventor Kaisa		Putkisto			
Art Unit		1762			
Examiner Name	F. Parker				
Attorney Docket Number		METSO-23			

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	d Issue Date Name of Patentee or Applicant   F		Releva	Pages,Columns,Lines when Relevant Passages or Rele Figures Appear				
	1	3930614		1976-0	1-06	Krenkel					
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	on Name of Patentee or Applicant of cited Document Passages					
	1										
If you wis	h to a	dd additional U.S. Publi		p		, , , , , , , , , , , , , , , , , , , ,		d button			
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	1	_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	nd publication Date Name of Patentee or Applicant of cited Document Pages, Column where Relevation Passages or Figures Appear			evant or Relevant	75	
	1										
If you wis	h to a	d additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	I-PATE	IT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Initiats* Cite Initiats* Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Тs				

	Application Number		10507417	
	Filing Date		2005-02-03	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor	Kaisa Putkisto		
	Art Unit		1762	
	Examiner Name	F. Parker		
	Attorney Docket Numb	or.	METSO.23	

1	ΙП
	_

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Patent Documents at inverUSPTO\_GOLY or MPEP 901.94. 2 Enter office that issued the document, by the involved own (WIPO Standard ST3.). \*Produces persist or counters, the oricidation of the year of the region of the Emperor many precedure the settle undervised the patent document. \*\*

\*\*Varied of counterity this appropriate symbols as endicated on the document under WIPO Standard ST1.64 (possole, \*2 Applicant is to place a check mark here it region is language treated ions is data-order.)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10507417	
Filing Date		2005-02-03	
First Named Inventor	Kaisa Putkisto		
Art Unit		1762	
Examiner Name	F. Parker		
Attorney Docket Number		METSO-23	

#### CERTIFICATION STATEMENT

Flease see 3/ CFR 1.5/	and 1.50 to make the appli	opriate selection(s).	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

# SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2006-08-01						
Name/Print	David R.J. Stiennon	Registration Number	33212						

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.3.231.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.